Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger
- PMID: 23612203
- PMCID: PMC3697322
- DOI: 10.1128/AAC.02383-12
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger
Abstract
Little is known about resistance of Plasmodium falciparum to antimalarials in Sahelian countries. Here we investigated the drug susceptibilities of fresh isolates collected in Niger post-deployment of artemisinin-based combination therapies (ACTs). We found that the parasites remained highly susceptible to new (dihydroartemisinin, lumefantrine, pyronaridine, and piperaquine) and conventional (amodiaquine and chloroquine) antimalarial drugs. The introduction of ACTs in 2005 and their further deployment nationwide have therefore not resulted in a decrease in P. falciparum susceptibilities to these antimalarials.
Figures
References
-
- WHO 2010. World Malaria report. WHO, Geneva, Switzerland: http://www.who.int/malaria/world_malaria_report_2010/worldmalariareport2...
-
- United Nations Development Programme 2007. Human development report/2008. Fighting climate change: human solidarity in a divided world. United Nations Development Programme, New York, NY: http://hdr.undp.org/en/media/HDR_20072008_EN_Complete.pdf
-
- WHO 2011. World health statistics. WHO, Geneva, Switzerland: http://www.who.int/gho/publications/world_health_statistics/EN_WHS2011_F...
-
- AMFm Task Force 2007. Affordable medicines facility—malaria (AMFm). Roll Back Malaria Partnership, Geneva, Switzerland: http://www.rollbackmalaria.org/partnership/tf/globalsubsidy/AMFmTechProp...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
